Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair - Full Text View

Purpose

The purpose of this study is to study the effects of Xolair using non-invasive techniques from the expired gas of patients with moderate to severe allergic asthma.

Condition	Intervention	Phase
Lung Disease	Drug: Placebo Drug: Xolair	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of Lung Disease After Treatment With Xolair

Resource links provided by NLM:

Genetics Home Reference related topics: allergic asthma

MedlinePlus related topics: Lung Diseases

Drug Information available for: Omalizumab

U.S. FDA Resources

Further study details as provided by Creighton University:

Primary Outcome Measures:

To assess the effect of Xolair on exhaled nitric oxide and leukotriene levels obtained from exhaled breath condensate in patients before and after four months of Xolair or placebo treatment. [ Time Frame: post dose ]

Secondary Outcome Measures:

To measure the levels of power of hydrogen (pH), nitrate/nitrite in exhaled breath condensate before and after four months treatment with Xolair and to compare these data to those obtained from the placebo asthmatic control group. [ Time Frame: post dose ]


Enrollment:	65
Study Start Date:	September 2005
Study Completion Date:	December 2009
Primary Completion Date:	December 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Placebo Saline placebo	Drug: Placebo Saline, Sub-Cuteanous (SQ) Other Name: Normal Saline
Experimental: Xolair Xolair treatment	Drug: Xolair Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ Other Names: omalizumab rhumabE25

Detailed Description:

Traditional methods of sampling secretions from the lower respiratory tract include sputum collection, sputum induction, and bronchoscopy with bronchoalveolar lavage. They cannot be repeated within a short period of time because of their invasiveness, and because the procedures themselves may include an inflammatory response. The need to monitor inflammation in the lungs has led to the exploration of exhaled gases and condensates. Noninvasive monitoring may assist in differential diagnosis of pulmonary diseases, assessment of disease severity and response to treatment.

Eligibility


Ages Eligible for Study:	12 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

On medium to high dose inhaled corticosteroids either with or without a long acting beta agonist
Baseline IgE 30-700 IU/mL
Exhaled nitric oxide greater than 13 ppb
Positive skin test to at least one of the following perennial allergens: cat, dog, dust mite, cockroach
Stable asthma at the time of enrollment

Exclusion Criteria:

Concurrent diseases/conditions, history of other diseases/conditions, with clinically significant uncontrolled systemic disease or a history of such disease (eg, infection, hematological, renal, hepatic, coronary heart disease or other cardiovascular disease, endocrinological, or gastrointestinal disease) within previous 3 months
Upper or lower respiratory tract infection within 6 weeks of screening visit
Elevated IgE level other than atopy
Known sensitivity to Xolair
< 3 months of stable immunotherapy
Smokers
Pregnant/nursing women
Women of childbearing potential who are not practicing medically approved contraceptive methods (eg, oral, subcutaneous, mechanical, or surgical contraception) including abstinence
Patients who currently hav diagnosed cancer, are currently being investigated for possible cancer or who have any history of cancer
Known sensitivity to study drug or class of study drugs
Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study
Use of any other investigational agent in the last 30 days.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00139152

Locations


United States, Nebraska
Creighton University Division of Allergy & Immunology
Omaha, Nebraska, United States, 68131
United States, New York
Albany Medical College
Albany, New York, United States, 12208

Sponsors and Collaborators

Creighton University

Novartis Pharmaceuticals

Investigators


Principal Investigator:	Robert G Townley, MD	Creighton University Division of Allergy & Immunology
Principal Investigator:	Muhammad A Pasha, M.D.	Albany Medical CollegeDivision of Allergy, Asthma, & Immunology

More Information


Responsible Party:	Creighton University
ClinicalTrials.gov Identifier:	NCT00139152 History of Changes
Other Study ID Numbers:	Xolair ENO EBC Study
Study First Received:	August 29, 2005
Last Updated:	January 6, 2014

Keywords provided by Creighton University:


moderate to severe allergic asthma

Additional relevant MeSH terms:


Lung Diseases Respiratory Tract Diseases Omalizumab	Anti-Allergic Agents Anti-Asthmatic Agents Respiratory System Agents

ClinicalTrials.gov processed this record on August 18, 2017